These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8618956)

  • 41. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.
    Singer I; Al-Khalidi H; Niazi I; Tchou P; Simmons T; Henthorn R; Holroyde M; Brum J
    J Am Coll Cardiol; 2004 Jan; 43(1):39-43. PubMed ID: 14715180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
    Page RL; Connolly SJ; Wilkinson WE; Marcello SR; Schnell DJ; Pritchett EL;
    Am Heart J; 2002 Apr; 143(4):643-9. PubMed ID: 11923801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.
    Nishida A; Reien Y; Ogura T; Uemura H; Tamagawa M; Yabana H; Nakaya H
    J Pharmacol Sci; 2007 Nov; 105(3):229-39. PubMed ID: 17965539
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide.
    Bril A; Forest MC; Cheval B; Faivre JF
    Cardiovasc Res; 1998 Jan; 37(1):130-40. PubMed ID: 9539867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials.
    Connolly SJ; Schnell DJ; Page RL; Wilkinson WE; Marcello SR; Pritchett EL;
    Am Heart J; 2003 Sep; 146(3):489-93. PubMed ID: 12947368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antiarrhythmic effect of TJ0711].
    Zhang XJ; Qiu J; Li G
    Yao Xue Xue Bao; 2014 Mar; 49(3):419-26. PubMed ID: 24961117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
    Black SC; Butterfield JL; Lucchesi BR
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of acute myocardial ischemia on the ventricular defibrillation threshold during chronic oral azimilide therapy.
    Chevalier P; Dubieff AD; Piqueras E; Pineau J; Rivard L; Morel E; Bui-Xan B; Timour Q
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):629-32. PubMed ID: 18091578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels.
    Yao JA; Tseng GN
    J Cardiovasc Electrophysiol; 1997 Feb; 8(2):184-98. PubMed ID: 9048249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Azimilide causes reverse rate-dependent block while reducing both components of delayed-rectifier current in canine ventricular myocytes.
    Gintant GA
    J Cardiovasc Pharmacol; 1998 Jun; 31(6):945-53. PubMed ID: 9641481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
    Dorian P; Al-Khalidi HR; Hohnloser SH; Brum JM; Dunnmon PM; Pratt CM; Holroyde MJ; Kowey P;
    J Am Coll Cardiol; 2008 Sep; 52(13):1076-83. PubMed ID: 18848141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.
    Löfberg L; Jacobson I; Carlsson L
    Europace; 2006 Jul; 8(7):549-57. PubMed ID: 16798770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide.
    Page RL; Tilsch TW; Connolly SJ; Schnell DJ; Marcello SR; Wilkinson WE; Pritchett EL;
    Circulation; 2003 Mar; 107(8):1141-5. PubMed ID: 12615792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats.
    Chen J; Komori S; Li B; Tamura K; Hashimoto K
    Br J Pharmacol; 1996 Nov; 119(5):937-42. PubMed ID: 8922743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
    Dorian P; Borggrefe M; Al-Khalidi HR; Hohnloser SH; Brum JM; Tatla DS; Brachmann J; Myerburg RJ; Cannom DS; van der Laan M; Holroyde MJ; Singer I; Pratt CM;
    Circulation; 2004 Dec; 110(24):3646-54. PubMed ID: 15533855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
    Chen J; Xue Y; Eto K; Ni C; Hashimoto K
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical differences between the newer antiarrhythmic agents.
    Camm AJ
    Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias and reperfusion-induced arrhythmias in anesthetized rats.
    Komori S; Li B; Matsumura K; Takusagawa M; Sano S; Kohno I; Osada M; Sawanobori T; Ishihara T; Umetani K; Ijiri H; Tamura K
    Mol Cell Biochem; 1999 Sep; 199(1-2):201-8. PubMed ID: 10544968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents.
    Fermini B; Jurkiewicz NK; Jow B; Guinosso PJ; Baskin EP; Lynch JJ; Salata JJ
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):259-71. PubMed ID: 7475051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.